ClinicalTrials.gg

Program

VX-993

A development code. Also written as “14C-VX-993”.

Its studies are mostly in Pain · Neuralgia · Acute Pain, led by Vertex Pharmaceuticals.

Furthest: phase 2, since Sep 27, 202410 company-led studies, 1 open or runningNext primary completion: Mar 25, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals101 open or runningphase 2since Sep 27, 2024Dec 7, 2022Mar 25, 2027phase 2 · NCT06619860

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 7, 2022First study: phase 1 study in PainFirst studyNCT05653323 · 70 enrolled · United Kingdom
  2. Dec 20, 2023Phase 1 study in PainNCT06226454 · 39 enrolled · United States
  3. Apr 25, 20242 phase 1 studies in PainNCT06392659, NCT06394167
  4. May 14, 2024Phase 1 study in PainNCT06420765 · 92 enrolled · United Kingdom
  5. Jul 12, 20242 phase 1 studies in PainNCT06508762, NCT06523595
  6. Sep 27, 20242 phase 2 studiesNCT06619860, NCT06619847
  7. Mar 14, 2025Phase 1 study in PainNCT06886269 · 8 enrolled · United States

Ahead

  1. Mar 25, 2027Primary completion: phase 2 study in Diabetic Peripheral Neuropathic PainNCT06619860

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06886269Pain · United States1CompletedMay 17, 20258
NCT06619860Diabetic Peripheral Neuropathic Pain · United States, Canada, France and more2RecruitingMar 25, 2027300
NCT06619847Acute Pain · United States2CompletedMay 27, 2025367
NCT06523595Pain · United States1CompletedDec 31, 202431
NCT06508762Pain · United States1CompletedSep 10, 202424
NCT06420765Pain · United Kingdom1CompletedMar 22, 202592
NCT06394167Pain · United States1CompletedFeb 18, 202588
NCT06392659Pain · United Kingdom1CompletedJul 2, 202442
NCT06226454Pain · United States1CompletedJun 12, 202439
NCT05653323Pain · United Kingdom1CompletedSep 12, 202370

How it is read

Names in the registry

  • “VX-993”, 9 entries
  • “14C-VX-993”, 1 entry

Codes read as this program: VX993.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.